CRVS Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals (CRVS) has drawn fresh attention after recent trading left the biotech down about 19% over the past month and 13% over the past 3 months from a US$11.80 close. That recent slide sits against a much stronger ride for Corvus Pharmaceuticals, with the share price return still up 61.2% year to date and the 1 year total shareholder return at 78.52%, while the 3 year total shareholder return is very large at roughly 7x. This indicates strong long term momentum even as short...

On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule. Soquelitinib, the company’s oral ITK inhibitor, is now being tested across five different diseases at once, from a rare blood cancer to asthma. That kind of breadth from a single-asset biotech is either a […]

Soquelitinib advances across multiple indications, with cash runway extended into 2028.

Corvus Pharmaceuticals Inc (CRVS) reports robust financials and progresses key clinical trials for soquelitinib across multiple indications.

Moby summary of Corvus Pharmaceuticals, Inc.'s Q2 2026 earnings call

Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected milestones across programs in peripheral T-cell lymphoma, atopic dermatitis, hidradenitis suppurativa and